MEDP
Medpace Holdings, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$619.66
+0.19%Year over year
Reported trailing growth
- Revenue
- +24.7%
- EBITDA
- +20.9%
- EBIT
- +22.2%
- EPS
- +25.8%
- Free cash flow
- +26.5%
- Operating cash flow
- +22.6%
Forward estimates
Based on analyst estimates
- Revenue
- +6.1%
- EBITDA
- +7.7%
- EPS
- +8.3%
Three-year CAGR
- Revenue
- +20.1%
- EBITDA
- +22.8%
- EBIT
- +24.3%
- Net income
- +22.5%
- EPS
- +27.4%
- Free cash flow
- +24.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026